- Home
- HCC vs DNLI Comparison
HCC vs DNLI Comparison
Compare HCC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCC
- DNLI
- Stock Information
- Founded
- HCC 2015
- DNLI 2013
- Country
- HCC United States
- DNLI United States
- Employees
- HCC N/A
- DNLI N/A
- Industry
- HCC Coal Mining
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HCC Energy
- DNLI Health Care
- Exchange
- HCC Nasdaq
- DNLI Nasdaq
- Market Cap
- HCC 2.3B
- DNLI 2.1B
- IPO Year
- HCC 2017
- DNLI 2017
- Fundamental
- Price
- HCC $52.79
- DNLI $13.97
- Analyst Decision
- HCC Strong Buy
- DNLI Strong Buy
- Analyst Count
- HCC 5
- DNLI 15
- Target Price
- HCC $70.25
- DNLI $33.85
- AVG Volume (30 Days)
- HCC 1.2M
- DNLI 1.5M
- Earning Date
- HCC 07-31-2025
- DNLI 07-31-2025
- Dividend Yield
- HCC 0.61%
- DNLI N/A
- EPS Growth
- HCC N/A
- DNLI N/A
- EPS
- HCC 2.01
- DNLI N/A
- Revenue
- HCC $1,319,451,000.00
- DNLI N/A
- Revenue This Year
- HCC N/A
- DNLI N/A
- Revenue Next Year
- HCC $34.02
- DNLI $323.34
- P/E Ratio
- HCC $26.11
- DNLI N/A
- Revenue Growth
- HCC N/A
- DNLI N/A
- 52 Week Low
- HCC $38.00
- DNLI $10.57
- 52 Week High
- HCC $75.15
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- HCC 62.05
- DNLI 50.96
- Support Level
- HCC $48.77
- DNLI $14.12
- Resistance Level
- HCC $54.40
- DNLI $15.15
- Average True Range (ATR)
- HCC 2.50
- DNLI 0.67
- MACD
- HCC 0.50
- DNLI 0.00
- Stochastic Oscillator
- HCC 85.37
- DNLI 47.90
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.